Niels van de Donk, MD, discusses initial safety and efficacy findings from the first-in-human study of JNJ-5322 in relapsed or refractory multiple myeloma.
Niels van de Donk, MD, PhD
Advertisement
Niels van de Donk, MD, PhD is an Associate Professor of Hematology, University Medical Center, Amsterdam, Netherlands.
Articles by Niels van de Donk, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5